Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

NCT05402722 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT05402722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05402722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2022
Completion date
June 30, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tnbc - triple-negative breast cancer